Ibuprofen 100mg/5mL; susp; berry, grape, or bubble-gum flavor; original or dye-free; alcohol-free. Use appropriate formulation and give every 6–8 hours. <6months ...

Prespecified primary analyses showed significant improvement over placebo in patients aged 71 and older and those with a baseline 6MWD below 333 meters.

In the phase 3 IZAR-1 trial, 42.1% of biologic-naïve adults with active PsA achieved ACR50 at week 16 in the sonelokimab 60mg with induction arm. Topline data were announced from a phase 3 trial ...

FDA issues CRL due to CMC and facility issues; no clinical data concerns were cited. The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to ITM regarding the New Drug ...

Credit: Getty Images. A medical malpractice case study demonstrates how accurate documentation of clinical decline without physician intervention led to an $8 million verdict. Documentation alone does ...

HealthDay News — A multistate outbreak of Salmonella infections has been linked to fresh jalapeño peppers imported from Sinaloa, Mexico, according to federal health officials.

Federal health officials have launched a nationwide clinical trial to find out whether a drug used to treat diabetes can help veterans cut back on drinking. The US Department of Veterans Affairs (VA) ...

Onabotulinumtoxin A is effective in decreasing headache frequency and disability of chronic migraine in pediatric patients, according to a study published onlin ...

Expanded indiction allows earlier radioligand therapy in PSMA-positive metastatic hormane-sensitive prostate cancer based on phase 3 PSMAddition trial data.

The FDA granted Priority Review to the supplemental NDA (sNDA) for levacetylleucine, an orally administered modified amino acid, in the treatment of ataxia-telangiectasia (A-T) in adult and pediatric ...

Supported by phase 3 SMART trial data, the application seeks to expand clesrovimab-cfor protection to high-risk children younger than 2 years entering their second RSV season.

FDA Fast Track designation for Aravax’s novel peptide immunotherapy PVX108 marks a significant milestone in expanding disease-modifying options for peanut allergy.